- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Abbreviated New Drug Applications and 505(b)(2) Applications
Fourth Quarter
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
| Reference Listed Drug | ANDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
|---|---|---|---|---|---|
| Apriso | Sunovion | mesalamine | Teva | Used to maintain remission of ulcerative colitis in patients 18 years of age and older | 10/1/2021 |
| Afinitor | Novartis | everolimus | Breckenridge | Used to treat postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole | 10/1/2021 |
| Afinitor | Novartis | everolimus | Biocon | Used to treat postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole | 10/4/2021 |
| BiCNU | Emcure | carmustine | Dr. Reddy's | Used to treat certain types of brain tumors; glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma and metastatic brain tumors | 10/15/2021 |
| Doxil | Baxter | doxorubicin | Padagis | Used to treat Ovarian Cancer, AIDS-related Kaposi’s Sarcoma and Multiple Myeloma | 10/21/2021 |
| Emerphed | Nexus | ephedrine sulfate | Par | Used to treat clinically important hypotension occurring in the setting of anesthesia | 10/26/2021 |
| Decadron | Merck | dexamethasone | Amneal | Used to treat several medical conditions, including respiratory complications associated with COVID-19 | 10/27/2021 |
| Akovaz | Exela | ephedrine | Dr. Reddy's | Used to treat clinically important hypotension occurring in the setting of anesthesia | 10/29/2021 |
| Antara | Lupin | fenofibrate | Lupin | Used as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolopoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia | 11/3/2021 |
| Desferal | Novartis | deferoxamine | Apotex | Used to treat acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias | 11/10/2021 |
| Samsca | Otsuka | tolvaptan | Camber / Hetero | Used to treat hyponatremia (low levels of sodium in your blood) in people with heart failure, and certain hormonal imbalances | 11/10/2021 |
| Targretin | Eisai | bexarotene | Teva | Used to treat cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy | 11/11/2021 |
| Zaditor | Alcon | ketotifen | Bayshore | Used to treat itchy eyes | 11/15/2021 |
| Zomig | iPR Pharmaceuticals | zolmitriptan | Padagis | Used to treat migraine headaches with or without aura in adults and pediatric patients (12 to 17 years of age) | 11/16/2021 |
| Zoloft | Pfizer | sertraline | Camber / Hetero | Used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD) | 11/19/2021 |
| Epiduo Forte | Galderma | adapalene / benzoyl peroxide | Teva | Used to treat acne vulgaris | 12/1/2021 |
| Brovana | Sunovion | arformoterol | Teva | Used for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema | 12/6/2021 |
| Diovan | Novartis | valsartan | Dr. Reddy's | Used to lower blood pressure, treat heart failure, or increase chances of survival after a heart attack | 12/9/2021 |
| Venlafaxine ER | Osmotica | venlafaxine | Dr. Reddy's | Used to treat Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD) with or without agoraphobia | 12/9/2021 |
| Daraprim | Vyera | pyrimethamine | Teva | Used to treat acute malaria in combination with other antimalarials only | 12/15/2021 |
| Carbaglu | Recordati | carglumic acid | Eton / ANI | Useed to treat acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency | 12/20/2021 |
| Marcaine | Hospira | bupivacaine | Hikma | Used in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures | 12/20/2021 |
| Northera | Lundbeck | droxidopa | Camber / Hetero | Used to treat low blood pressure that causes severe dizziness or a light-headed feeling | 12/21/2021 |
| Narcan | Adapt | naloxone HCl | Teva | Used to treat an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness or not being able to respond | 12/22/2021 |
| Sutent | Pfizer | sunitinib | Teva | Used to treat advanced renal cell carcinoma | 12/22/2021 |
| Narcan | Adapt | naloxone HCl | Sandoz | Used to treat an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness or not being able to respond | 12/22/2021 |
| Butrans | Purdue | buprenorphine | Teva | Used to manage pain severe enough to require daily, around-the- clock, long-term opioid treatment and for which alternative treatment options are inadequate | 12/27/2021 |
GENERICally Speaking Hatch Waxman Bulletin
Related Professionals
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.